Company intelligence / Profile preview
Gain Therapeutics
Bethesda, Maryland, United Statesgaintherapeutics.com ↗
- Ownership
- Public · GANX
- Employees
- ~25
- Development stage
- Phase 1
01
Overview
GT-02287, the lead drug candidate, is in Phase 1b clinical trials for Parkinson’s disease and has shown promising preclinical results in restoring GCase activity and reducing toxic lipid substrates.
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Small moleculesallosteric modulators
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Financials
- Market cap
- $41M
- Total revenue
- $0
- Enterprise value
- $28.5M
Beyond the preview
Go deeper on Gain Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gain Therapeutics.